Morning Brief — Tuesday, September 22, 2026

Market Overview

Monday’s AI-driven rally is carrying momentum into Tuesday, with the Nasdaq leading after ARM CEO Rene Haas declared chip demand “off the charts,” AMD crossed the $1 trillion market cap threshold, and Meta’s Muse AI agent hit #1 on the App Store. The Fed has moved rates to 3.75%–4.00% with at least one more hike signaled, keeping the 10-year yield around 5.0%, but bulls are treating AI capex demand as a higher-rate offset. Geopolitical noise (US-Iran Hormuz diplomacy, US-Greenland security pact) is adding color to specific pockets — energy easing, rare earths spiking — while the broader tape remains constructive but extended after back-to-back big up days.

Claude’s Call

UP — The AI momentum cycle has genuine fundamental underpinning today (ARM CEO confirmation, VKTX clinical data, MRNA ESMO slot), and with oil pulling back on Iran diplomacy hopes reducing the inflation impulse, the S&P 500 should grind modestly higher; the real risk is that yesterday’s 3% Nasdaq rip already front-ran the good news, so gains today will be shallower and more selective — expect tech to lead, consumer discretionary to lag.

Top Movers

CRML (+38.6%) — $9.33 → $10.89 (+16.7% upside from prior close, now targeting fib 38.2% resistance) Thesis: Pure Trump-policy pump — the US-Greenland security deal lit a fire under rare earth stocks, and CRML’s Tanbreez project is the largest rare earth deposit in Greenland, making this a logical beneficiary. The problem? Production is still years away, the refinery in Romania is in blueprint stage, and the 90-day return is still -31%. This is a sentiment-driven short squeeze on geopolitical news, not a fundamental re-rating — historically these “Trump security deal” rallies fade within 48-72 hours as reality sets back in. Levels: Exit at $10.89 (fib 38.2% resistance from 6mo swing). Support at $8.69 (fib 61.8%) — a breach of that puts you back near $6.35, the 20d low.

GRAL (+33.7%) — $107.97 → $124.93 (+15.7% upside) Thesis: This is a real catalyst with a hard date attached — the FDA Molecular and Clinical Genetics Panel meets September 23 to review the Galleri multi-cancer early detection test, and staff briefing documents showed no major safety or accuracy concerns. That’s the clearest pre-approval green light you can get short of the actual approval. GRAL is making a new 6-month high ($107.97 = the 6mo ceiling), and analyst mean target of $79 is now 27% below the stock — a classic case where the Street hasn’t caught up. Event-driven momentum here is real, not sympathy. Levels: Exit at $124.93 (fib 1.272 extension). Watch the $93.26 (fib 23.6%) as first support if the panel surprises negatively — that’s your hard stop on a binary catalyst.

VKTX (+23.6%) — $37.21 → $46.04 (+23.7% upside) Thesis: Viking Therapeutics’ VK2735 showed it can maintain most prior weight loss with less-frequent dosing — that’s a genuine differentiation point in the GLP-1 maintenance market where Lilly and Novo are both struggling with patient compliance on weekly injections. Less-frequent dosing could be a commercial moat. Vol ratio confirms conviction at 4.13x average, the only name today with meaningful volume confirmation. Technically, the stock is trading right at the fib 38.2% retracement ($36.64) from the 6mo swing, which is textbook pullback-bounce territory after the premarket spike. Levels: Exit at $46.04 (fib 1.272 extension). Support at $36.64 (fib 38.2%) / $34.94 (fib 50%) — if it can’t hold $36.64 on any intraday dip, the move fades. Stop-loss reference: $33.24 (fib 61.8%).

ARM (+17.2%) — $322.90 → $367.60 (+13.8% upside) Thesis: CEO Rene Haas told CNBC demand is “off the charts” and specifically voiced growing confidence in beating the $2B AGI CPU revenue target — that’s not boilerplate CEO confidence, that’s a specific, quantified revenue call above consensus. The stock’s 43 analysts carry a mean target of $289, meaning the stock has blown through the Street consensus by ~12%. Technically, ARM is sitting right at the fib 38.2% retracement level ($323.14) of the 6-month swing — meaning today’s price is almost exactly at a critical test. Holding here bullishly suggests continuation toward $367.60 (fib 23.6%). Levels: Exit at $367.60 (fib 23.6%). Support at $287.21 (fib 50%) / $261.51 (SMA 50). A weekly close below $287 would reverse the bull thesis entirely.

FSLY (+14.9%) — $27.42 → $29.42 (+7.3% upside to fib resistance; longer-term $38.20) Thesis: The AI security product launches (AI Firewall, AI Runtime Control, API Security) are company-specific catalysts, not just sector sympathy — Fastly is monetizing edge security in the AI agent era, a real TAM expansion. Investor Day today (September 22) adds a near-term catalyst. However, the RSI at 18.7 was deeply oversold before this move, which explains the size of the bounce but also means we’re running from a deeply washed-out base. The insider CTO sale of $825K worth of shares after a 177% YTD run is a yellow flag — insiders sold into strength, which typically means they see limited near-term upside. Caution on chasing above $29.42 (fib 23.6% resistance). Levels: Exit at $29.42 (fib 23.6% from 6mo high). Support at $26.90 (fib 38.2%) / $23.38 (SMA 50). Investor Day disappointment would snap this back fast.

AXTI (+14.1%) — $79.93 → $88.90 (+11.2% upside) Thesis: S&P SmallCap 600 index inclusion is a mechanical, forced-buying catalyst — passive funds must buy shares, and that demand is real and non-negotiable regardless of fundamentals. AXTI also plays into the “secret semiconductor substrate” InP (indium phosphide) story for AI/photonics interconnects, which is a genuine structural growth driver. The stock is up 284% YTD but the index inclusion resets the technical picture somewhat. Sitting near fib 61.8% retracement ($76.64) and well above the SMA 50 ($64.03). Levels: Exit at $88.90 (fib 50% resistance from 6mo swing). Support at $76.64 (fib 61.8%) / $64.03 (SMA 50). If index rebalancing buying completes before end of week, momentum buyers could exit and leave a vacuum.

FIVN (+14.0%) — $37.01 → $43.70 (+18.1% upside) Thesis: Five9 is hitting a fresh 52-week high with RSI at 21.6 before this move, making it one of the most oversold recoveries on the list — this is a genuine mean-reversion breakout, not a momentum chase. The catalyst appears to be broader SaaS/software relief from falling Treasury yields and improved US-China sentiment, but Five9’s contact center AI automation is a real secular story. The stock is trading at a forward P/E of 9.7x vs. a peer median of 40.1x — it’s flagged CHEAP by over 75% vs. peers, making it one of the most compelling valuation setups on the board. Levels: Exit at $43.70 (fib 1.272 extension). Support at $31.68 (fib 23.6%) / $30.62 (SMA 50). The stock is at its 6mo high — prior resistance becomes support, but a miss on guidance would unwind quickly.

ALAB (+12.4%) — $340.74 → $392.69 (+15.2% upside) Thesis: Sector sympathy from the broader AI semiconductor rally — no company-specific news today, just Astera Labs riding AMD’s $1T moment and ARM’s demand commentary. That’s not the strongest reason to buy, but Astera’s connectivity chips are direct infrastructure plays on AI datacenter builds, so the correlation is legitimate. 26 analysts have a mean target of $390, almost exactly at the fib 23.6% resistance level, suggesting the Street sees limited additional upside from here in the near term. Levels: Exit at $392.69 (fib 23.6% / analyst consensus). Support at $336.81 (fib 38.2%) / $303.62 (SMA 50). Already extended from $252 in 20 days — don’t chase if you’re not already in.

AKAM (+12.3%) — $117.41 → $124.99 (+6.4% upside to fib 50%) Thesis: Akamai’s AI security narrative is real — 87% of organizations had an API security incident in 2025, and the MuleSoft collaboration for API/AI governance is a genuine product-market expansion. RSI at 3.78 was almost historically oversold before this move, signaling this is a technical snapback as much as a fundamental re-rating. The stock is trading right at the fib 61.8% support-turned-resistance ($116.46), which it just cleared — that’s constructive. Levels: Exit at $124.99 (fib 50% resistance from 6mo swing). Support at $116.46 (fib 61.8%) / $113.70 (SMA 50). Conviction move or dead cat? Today’s Investor Day from Fastly (a peer) will set the tone for the entire edge cloud security complex.

INTC (+12.1%) — $121.78 → $140.94 (prior 6mo high, +15.7% upside) Thesis: Intel’s 12%+ move is riding AMD’s coattails into the CPU demand narrative — the AI chip supercycle is finally giving Intel credibility as a CPU supplier to AI workloads again. The SMA 50 was at $97.71 just recently and Intel has ripped to $121.78 — a 25% move in a week. The Fib 23.6% support at $117.40 is now just below the current price, meaning the stock is pressing against its first major technical test. At $121.78 vs. a 6mo high of $140.94, there’s still 15.7% to the prior peak. Levels: Exit at $140.94 (6mo high). Support at $117.40 (fib 23.6%) / $102.84 (fib 38.2%). Key risk: this is still Intel — execution on 18A process and actual AI revenue share gain are far from proven.

META (+11.4%) — $741.25 → $809.17 (+9.2% upside) Thesis: Meta Muse AI agent hitting #1 on the App Store is a legitimate consumer-facing AI monetization proof point — not just capex spending, but actual user adoption. Wells Fargo raising to $796 provides near-term price discovery. META is at its all-time 6-month high, RSI neutral (50), meaning momentum is healthy but not overheated. The AI agent + advertising flywheel is the most credible monetization story in the group. Levels: Exit at $809.17 (fib 1.272 extension). Support at $695.61 (fib 23.6%) / $662.97 (fib 38.2%). Amazon blocking Muse from its platform is a real competitive threat that bulls are brushing aside too quickly.

MRNA (+12.3%) — $172.94 → $209.47 (+21.1% upside) Thesis: The ESMO Presidential Symposium slot for the personalized cancer vaccine (intismeran autogene + Keytruda) data presentation on October 24 is a real, time-stamped catalyst — Presidential Symposium is the top billing at the world’s largest oncology conference. Combined with FDA clearance of updated COVID vaccines, Moderna is firing on two cylinders simultaneously. RSI at 50, near 6mo high, well above SMA 50 ($102.31) — clean uptrend. Levels: Exit at $209.47 (fib 1.272 extension). Support at $143.93 (fib 23.6%) / $125.10 (fib 38.2%). Binary risk on October 24 data presentation — this is a hold until ESMO, then reassess.

WBD (+10.8%) — $30.80 → $32.31 (+4.9% upside to fib 1.272) Thesis: Paramount settling the state antitrust lawsuit clears a concrete path to the Paramount-Warner Bros. Discovery megamerger — that’s genuine deal progression, not rumor. WBD is at a fresh 6-month high, RSI is elevated at 75.8 (the only overbought name on the list), and the fib 1.272 extension is only $32.31. Limited upside left at current prices; the deal premium is largely in. Levels: Exit at $32.31 (fib 1.272 extension). Support at $29.50 (fib 23.6%) / $28.69 (fib 38.2%). RSI at 75.8 is flashing caution — don’t chase this one here, let it pull back to $29.50 for a better entry.

Headlines to Watch

ARM CEO says chip demand is “off the charts,” eyes $2B AGI CPU target — Directly upgrades the revenue trajectory for the entire semiconductor ecosystem; if the $2B target is beatable, ARM justifies a premium multiple and the sell-side mean target ($289) becomes stale — upgrade cycle incoming.
GRAIL FDA panel meeting September 23: Staff docs show no major safety/accuracy issues with Galleri test — Binary binary binary — tomorrow’s panel verdict will either confirm Monday’s 34% gain or reverse it; if you’re holding GRAL overnight, you’re making a binary bet on a regulatory committee vote.
Paramount settles state antitrust suit, clearing path for Warner Bros. Discovery megamerger — The entertainment consolidation trade has legs; WBD and PARA holders get deal certainty premium, but the combined entity’s streaming vs. linear TV transition story remains the long-term question.
Viking Therapeutics VK2735 shows maintenance efficacy with less-frequent dosing — A potential moat in GLP-1 durability; watch Eli Lilly (LLY) and Novo Nordisk (NVO) for sympathy weakness — today’s Lilly entry call from a major bank ($37% upside) may actually look better if Viking is eating into their addressable market.
Meta Muse AI agent hits #1 on App Store; Amazon blocks Muse from its platform — Two sides of the same coin: consumer AI adoption is accelerating, but platform wars are real; Amazon’s block is a reminder that distribution risk for AI agents is structural, not trivial.
Fed at 3.75%–4.00%, signals at least one more hike; 10-year yield ~5.0% — The macro ceiling is still in place; any AI rally that runs too far can be unwound quickly if inflation data disappoints — keep position sizing in check on the high-duration growth names.
BlackBerry QNX design win (Coretura truck platform) + Cramer buy call ahead of earnings — Two different catalyst types colliding before the earnings print; the actual QNX royalty backlog data tomorrow morning is the only thing that matters — Cramer calls and design wins without revenue timelines are noise.

Claude’s Top Picks

FIVN (+14.0% today, +16.6% week) — $37.01 → $43.70 (+18.1% upside) Valuation: Flagged CHEAP — forward P/E of 9.7x vs. peer median 40.1x, trading at 76% discount to contact center/SaaS peers, one of the widest valuation gaps in software. Upside: Breaking to a new 6-month high from deeply oversold conditions (RSI was 21.6 pre-move), with AI contact center automation as a genuine secular growth driver and clear runway to $43.70 fib extension. Risk: No specific company catalyst today (sector sympathy/rate relief driven), meaning if yields reverse or the AI rally stalls, the valuation discount won’t protect you in the near term; SMA 50 at $30.62 is a long way down.

VKTX (+23.6% today, +24.2% week) — $37.21 → $46.04 (+23.7% upside) Valuation: Pre-revenue clinical stage, so traditional P/E is meaningless (negative); peer comparison is other late-stage obesity pipeline names — the less-frequent dosing differentiation could command a premium pipeline multiple vs. ZEPBOUND/Wegovy maintenance competitors. Upside: 4.13x volume ratio is the only genuine volume confirmation on the entire top-20 list today, validating the move; VK2735 maintenance data is a regulatory and commercial inflection point in a multi-hundred-billion-dollar obesity market. Risk: Clinical-stage binary — any adverse signal in the follow-on data, a competitive response from Lilly (who has a $37% upside entry call today), or a broader biotech risk-off could erase 30%+ in a session; stop-loss at fib 61.8% ($33.24).

MRNA (+12.3% today, +17.9% week) — $172.94 → $209.47 (+21.1% upside) Valuation: Not available in comps data, but MRNA at $173 vs. SMA 50 at $102 shows how dramatically sentiment has shifted; the stock has more than tripled off its 6-month low ($45.37), meaning it’s no longer cheap but the ESMO catalyst re-rates the pipeline value. Upside: October 24 ESMO Presidential Symposium data is a hard-date catalyst with a top-billing slot — personalized cancer vaccines + Keytruda combination is the hottest oncology theme at the world’s largest cancer conference; that’s a 32-day hold for a defined catalyst event. Risk: Presidential Symposium slots can cut both ways — if the data is positive but not incrementally better than Phase 2, the “sell the news” reaction could be severe; also, the stock is near its 6-month high ($174.38) and already up 17.9% this week, leaving less margin for error.

ARM (+17.2% today, +35.1% week) — $322.90 → $367.60 (+13.8% upside) Valuation: EXPENSIVE at 105.7x forward P/E vs. peer median 18.9x, and EV/EBITDA of 321x vs. peer median 30.5x — but for a 22.4% grower with CEO-confirmed above-consensus revenue targets, the growth premium is defensible if the $2B AGI CPU call is correct. Upside: CEO-specific, quantified revenue guidance above consensus is among the strongest short-term catalysts in this list; analyst mean target of $289 will be revised upward materially in the next 2-4 weeks as sell-side catches up, creating a mechanical upgrade-driven drift. Risk: The valuation is objectively extreme — 105x forward P/E and 321x EV/EBITDA leave zero room for any execution miss; and with a 35% weekly gain already in the bag, the risk/reward deteriorates quickly above $340.

INTC (+12.1% today, +25.3% week) — $121.78 → $140.94 (+15.7% upside) Valuation: Not in comps table, but Intel at $121 vs. a 6-month low of $41.19 represents a near 3x move — the market is clearly pricing in a CPU renaissance; relative to AMD (now $1T), Intel still trades at a steep discount despite the shared CPU demand narrative. Upside: If the AI CPU demand cycle is real (ARM CEO confirms, AMD crosses $1T), Intel is the last major semiconductor name still below its prior highs — the 6-month high of $140.94 is the natural technical target and represents 15.7% from here. Risk: Intel is the most execution-risk semiconductor name in the sector — 18A process delays, market share losses to AMD, and a history of disappointing on guidance make this a “show me” story; the 25% weekly gain may already be pricing in a recovery that hasn’t been delivered yet.

Avoid

CRML — Pure geopolitical event-driven pump on a US-Greenland security deal with no near-term production catalyst; the Tanbreez refinery is in blueprint stage, production is years away, the 90-day return is still -31%, and “Trump security deal” rallies in speculative miners have a consistent track record of giving back 50-80% of the move within a week — this is a trade for those who got in at $5, not at $9.33.

WBD — RSI at 75.8 is the most overbought reading on the entire list, it’s sitting at a fresh 6-month high with only $1.51 (4.9%) to the fib 1.272 extension at $32.31, and deal-close certainty premium is largely priced in following the antitrust settlement — the merger risk now shifts to integration execution and the secular decline of linear TV, making this a sell-the-news setup more than a momentum buy.

GRAL — Binary event risk with the FDA panel vote tomorrow (September 23) — yes, the staff documents were positive, but a panel vote can go sideways for reasons that have nothing to do with the briefing docs (committee member concerns, label disputes, post-market requirements), and the stock is already trading at its 6-month high with the mean analyst target 27% below the current price; the risk/reward on holding through a binary FDA vote at these levels favors caution over conviction.

WSB Sentiment Check

META — WSB says: BULLISH (80% bullish) Claude says: AGREE — The Muse App Store #1 is genuine consumer AI adoption proof, Wells Fargo’s target raise to $796 gives near-term price discovery, and META is at its all-time 6-month high on healthy (not overheated) RSI of 50; the chart supports the thesis, and the AI monetization story is the best in mega-cap tech right now — just don’t ignore that Amazon blocking Muse is a real distribution risk.

AMD — WSB says: BULLISH (80% bullish, 5,862 upvotes) Claude says: PARTIALLY AGREE — AMD crossing $1 trillion is a milestone, not a catalyst; the AI CPU demand story is real and validated by ARM’s CEO today, but AMD at $615 vs. a 6-month low of $196 is a 3x move in six months — the SMA 50 at $498 is 19% below current price, meaning there’s a lot of air under this stock if sentiment shifts; WSB is right on the direction but wrong to be chasing strength this aggressively at all-time highs with the Fed still hiking.

MU — WSB says: BULLISH (80% bullish) Claude says: AGREE — Micron at $1,046 is riding the AI memory supercycle (HBM demand for AI accelerators), and the technical picture shows the stock holding above SMA 50 ($930) with fib 1.272 extension at $1,455 as the next target — that’s 39% additional upside from current levels; the memory cycle is earlier innings than the compute cycle, making MU one of the more legitimate momentum plays in the group.

NVDA — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — NVDA at $229 is consolidating just below its 6-month high ($235.20), sitting above SMA 50 ($214.92), with the fib 1.272 extension at $254.35 as the next target; the chart is fine and the AI infrastructure demand story is unimpeachable, but the 0.06 vol ratio today suggests this isn’t where the smart money is adding — it’s the safe AI trade, not the alpha AI trade right now; if you’re in, hold; don’t add chasing.

INTC — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Intel’s CPU demand revival narrative has real legs in the AI era, and the technical setup (breaking above fib 23.6% at $117.40) is constructive with room to the 6-month high at $140.94; but WSB’s 80% bullishness on Intel specifically is historically a contrarian signal — Intel has burned bulls before with process delays and guidance cuts, and a 25% weekly move in a turnaround stock that hasn’t actually turned around yet deserves more skepticism than WSB is applying.

Earnings Scorecard

BB (BlackBerry) — REPORTED | EPS: $0.10 | Stock: +6.9% The +7% reaction reflects genuine excitement about QNX design wins and Cramer’s buy call ahead of the print, but the actual earnings quality ($0.10 EPS with no comparative estimate to benchmark against) makes this hard to call a beat — reaction looks justified for a turnaround-narrative stock; watch the actual QNX royalty backlog numbers in the report to determine if this is buy-the-earnings or sell-the-news at $9.71 analyst target.

SNX (TD SYNNEX) — REPORTED | EPS: $13.95 | Stock: +5.1% Solid reaction for an IT distributor — TD SYNNEX is a direct beneficiary of enterprise AI hardware refresh cycles, and a +5% move on earnings is a sign of genuine beat expectations; at analyst target of $334, there’s still meaningful upside — this is a quiet buy-the-dip if it pulls back.

AZO (AutoZone) — REPORTED | EPS: $145.34 | Stock: +3.4% CEO commentary that the company is “well-positioned for sales growth in fiscal 2027” paired with a revenue miss but EPS beat is a mixed bag — the market’s +3.4% reaction is probably right-sized; AutoZone is a defensive compounder, not a momentum trade; hold if you own it, no reason to chase.

ADYEY (Adyen) — REPORTED | EPS: $0.41 | Stock: +2.0% Raised growth guidance is the key line here — a payments processor that beats and raises in a high-rate environment is demonstrating pricing power; the muted +2% reaction probably reflects the European ADR liquidity discount; legitimate hold/add on any weakness for investors with a 6-12 month horizon.

ABVX (Abivax) — REPORTED | EPS: -$5.29 | Stock: -2.0% Clinical-stage losses are expected, so the -$5.29 EPS is less meaningful than pipeline progress; the -2% reaction is mild and may reflect headline reading of the EPS number without context — hold if you have thesis conviction on the ulcerative colitis pipeline, exit if you don’t.

DRI (Darden Restaurants) — REPORTED | EPS: $10.44 | Stock: +1.8% Solid beat in a challenging restaurant environment — the +1.8% reaction is slightly underwhelming but reflects the stock’s premium multiple going in; Cramer’s pre-earnings preference for EAT over DRI looks like it may have been wrong; Darden is a quality hold, not a trader’s name.

GIS (General Mills) — REPORTED | EPS: -$0.16 | Stock: +1.3% Negative EPS with a positive stock reaction suggests either massive beat vs. a deeply negative estimate or some write-down/one-time item distortion — without the estimate context, the +1